Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials

Authors:

Abstract
No abstract available
Funding Information
  • Roche
  • F. Hoffmann-La Roche

This publication has 20 references indexed in Scilit: